Skip to main content

Treatment

With the lethality, availability and use of stimulants all greatly increasing in the U.S. in recent years and the COVID-19 pandemic complicating the treatment landscape for patients and practitioners alike, it’s critical for providers to weather the storm, Deni Carise, PhD, chief science officer for Recovery Centers of America, told Cocaine, Meth & Stimulant Summit attendees in a Saturday session.
With methamphetamine and cocaine use on the rise across the U.S. and no medications as yet approved by the FDA, a combination of contingency management and community reinforcement is the most effective treatment modality for treating stimulant addiction, NIDA director Nora Volkow, MD, said in a Stimulant Summit keynote.
Judge Kevin R. Mullins, of Kentucky’s 47th district, explains how helping defendants connect with treatment and other community-supported initiatives have helped Letcher County respond first to the opioid crisis and now a surge in methamphetamine use.
Eric S. Talbot, MS, assistant director of ONDCP’s National Cocaine Coordination Group and a presenter at the upcoming Cocaine, Meth & Stimulant Summit, discusses his office’s efforts to monitor drug trends, expand treatment and mitigate the challenges of COVID-19.
Half of clinicians who are waivered to prescribe buprenorphine for the treatment of opioid use disorder have actually done so, and a majority are prescribing the medication for a number of patients that is well below the limit for which they are waivered, according to a new study.
Back to Top